Correct staging is the most crucial for the treatment outcome in cancer management. Molecular imaging with 18
Introduction
Population-based cancer registry has documented that breast cancer has become a leading cancer in India in many cities and has been projected as the number one cancer in future. [1] Correct staging and early diagnosis are what matters the most in patient management. Cancer imaging has grown from morphological imaging to molecular imaging in recent decades. 18 F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) has already proved it in many clinical scenarios. [2] [3] [4] [5] [6] In breast cancer, 18 F-FDG PET-CT commonly is being asked for in locally advanced cancer for metastatic workup, for response evaluation and in suspected recurrence. 18 F-FDG PET-CT exploits the high glucose turnover in cancer cells compared to normal cells. [7, 8] It is a well-known fact that granulocytes and activated lymphocytes also exhibit significantly increased glucose uptake and in many occasions, it creates a diagnostic dilemma in 18 F-FDG PET-CT interpretation. [9, 10] Molecular targeted imaging radiopharmaceuticals will not only improve the diagnostic specificity but will also facilitate a better understanding of the treatment outcomes. [11] Estrogen receptor-positive (ER+) breast cancer is the most common type diagnosed today. [12] According to the American Cancer Society, about two out of every three cases are hormone receptor-positive. The understanding of the ER expression has an impact on both treatment planning and prognosis. [13] In present practice, ER expression is measured on the pathological sample by immunohistochemistry (IHC). However, there may be heterogeneity in the receptor expression at primary and metastatic sites in approximately 20% of patients. [14, 15] In these cases, a single biopsy may not be representative of the ER expression of the whole disease burden. 16-α-( 18 F)-Fluoro-17-β-Estradiol ( 18 F-FES) is a radiolabeled ligand of the ER and has been investigated since 1988. [ 
16] 18
F-FES PET-CT has shown good correlation with ER expression. [17] [18] [19] [20] 18 F-FES PET-CT will not only instrumental in revealing ER expression heterogeneity but will also add specificity to the diagnosis. The aim of this prospective study is to compare the diagnostic strength of 18 F-FES PET-CT in comparison to the existing standard 18 F-FDG PET-CT and also to look for the impact of 18 F-FES PET-CT in Indian female patient management. Recently, 18 F-FES PET-CT has been presented as a diagnostic tool in breast cancer patients with a clinical dilemma; [21] however, we have not seen any study comparing the diagnostic strength of these two tracers. This paper details the utilization of 18 F-FES for PET-CT studies at the clinical level for the first time in India.
Materials and Methods

Patients
Twelve female patients were prospectively included in the study between December 2014 and September 2015, and the protocol was approved by the Hospital Medical Ethical Committee. All patients provided written informed consent. Patients with pathologically proved breast cancer referred for staging, restaging, or treatment response evaluation were included in the study. The study does not include patients on tamoxifen or fulvestrant; however, patients on aromatase inhibitors were included in the study. Patients with Eastern Cooperative Oncology Group performance status ≤2 and off chemotherapy for at least 3 weeks were included. All eligible patients underwent 18 F-FDG PET-CT and 18 F-FES PET-CT in the Nuclear Medicine Department of Rajiv Gandhi Cancer Institute and Research Centre within 1 week interval time. Of the 12 patients, two patients had negative ER expression and the remaining ten patients were ER+.
Scan protocols
Standard
18 F-FDG PET-CT protocol was used. [22] All patients were instructed for fasting for at least 4 h, preceded by a light meal and to maintain good hydration. After injecting 4-5 MBq/kg body weight of 18 F-FDG intravenously, patients were rested for 1 h in a silent, dimly lit isolation room, and administered 1 L of plain water orally. The scan was performed on a dedicated full ring hybrid PET-CT system (Biograph TruePoint40 Siemens Healthcare with LSO crystal) with 2 min per bed position in three-dimensional mode starting from base of the skull to mid-thigh. A low dose CT scan (40 mAs and 120 kVp) was performed first for attenuation correction and anatomical localization in all patients. 18 F-FES was procured from the Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, India, in a ready to use vial. The synthesis of 18 F-FES was performed with cyclic estradiol sulfate 3-O-methoxy-methyl-16β, 17β-epiestriol-O-cyclic sulfone as a precursor. Nucleophilic substitution using a disposable cassette system for GE TRACERlab™ MX-FDG was performed and the purification is carried out by solid phase extraction cartridges. 18 F-FES was produced in 18.2 ± 3.0% no-carrier-added (specific activity 100-200 GBq/µmol). The chemical and radiochemical purity were >95% and >99%, respectively. Same preparation instructions and imaging protocol as for 
Image interpretation
Tumor 18 F-FDG and 18 F-FES uptake were analyzed by the nuclear medicine physician both visually and semi-quantitatively. For semi-quantitative analysis, maximum standardized uptake value (SUVmax) corrected by body weight (SUVmax) was calculated. In organs with extensive and uncountable lesions, an arbitratory maximum number of 10 lesions were taken for calculation. A lesion showing significant (more than adjacent background) uptake on visual analysis by two independent nuclear medicine physicians was taken as positive. SUVmax was calculated for both 18 F-FDG and 18 F-FES for biopsy-proven lesions sites.
18 F-FES-positive lesion was taken as a true positive for disease and as a reference in case of indeterminate lesion on 
Statistical analysis
A number of lesions suspected for disease by 18 F-FDG and 18 F-FES were calculated out of a total number of lesions seen by either of them together and their sensitivities were calculated and compared with. Because liver lesions were not appreciable on 18 F-FES scan due to high physiological uptake in liver, sensitivities were also calculated for lesions excluding liver lesions and compared with. Table 6 and Figure 1 ]. P value was not significant with the level of ER expression and 18 F-FDG or 18 F-FES SUVmax; however, a positive trend was seen with 18 F-FES SUVmax and ER expression (P trend 0.011). Looking at the trend chart, negative trend of ER expression with 18 F-FDG uptake was also appreciated (P trend 0.118). F-FES uptake; [16] [17] [18] [19] [20] however, the use of FES imaging has not been explored much, especially in the clinical setting. Peterson et al. have compared 18 F-FES PET and ER expression. [18] Similarly, in our analysis, two ER-negative patients on IHC showed no significant 18 F-FES uptake whereas the remaining ten ER+ patients showed 18 F-FES scan helped in the characterization of these lesions to a great extent. 18 F-FES PET-CT was positive in eight while negative in seven in these MLNs. In all 13 lung lesions, 18 F-FES scan was positive [ Figure 2 ] which is remarkable finding from a clinical management point.
F-FES
It has been reported that breast carcinoma metastasis is the most common carcinoma encountered by the dermatologist and presents in various forms. [23] Scalp nodules in patient number 6 (ER 100%) were one of the clinical findings and thought to be either multiple furunculosis or metastatic. The scalp nodules were 18 F-FDG-positive but this did not solve the problem. Good tracer uptake on 18 F-FES PET-CT helped in the characterization of the nature of the scalp nodules as metastatic [ Figure 3 ]. In the same patient, the mass in the periampullary region causing common bile duct obstruction was also seen on 18 F-FDG PET-CT, which definitely required characterization as either metastatic or second primary. Being an uncommon site of metastasis and obstructive in nature, endoscopy was advised, which was refused by the patient. 18 F-FES PET-CT scan was most helpful in solving this issue. 18 F-FES uptake in periampullary mass has simulated breast origin in this setting [ Figure 4 ]. F-FES PET-CT scan showed good tracer uptake in the all known and new metastatic sites; hence, hormone treatment (aromasin) was considered.
The only shortcoming for 18 F-FES PET-CT scan is in diagnosing liver lesions. Due to metabolism of 18 F-FES in the liver, it showed very high physiological uptake. Indeed, a fasting status is much needed to downregulate the liver enzymatic activity to reduced background uptake. In our case, liver background tracer uptake was very high (SUVmax range: 12.5-18.7); hence, big lesions (>1 cm) appeared relatively cold and small lesions (<1 cm) were not appreciable. Despite these, SUVmax in large lesions was fair (SUVmax range: 3.3-7.0). Indeed, the issue of low sensitivity for liver metastasis for 18 PET-CT is similar to brain lesions sensitivity for 18 F-FDG PET-CT. In both situations physiological uptake limits the diagnostic strength. In view of this, we calculated the sensitivity of both tracers for nonhepatic metastatic sites, and there was no significant difference found (P = 0.216).
ER expression was available for one site in each patient; hence, ER expression correlation was done for ten sites only. In view of the very small number of the lesions, the median value of SUVmax was used for analysis. A positive correlation was found with 18 F-FES SUVmax and ER expression (P = 0.009) while no correlation was seen with 18 F-FDG SUVmax (P = 0.148). For assessing the change in ER expression and SUVmax of lesions on 18 F-FDG and 18 F-FES, a trend analysis was also done. A negative trend was noticed with increasing ER expression and SUVmax of 18 F-FDG, however P trend was not significant (P trend 0.118). For 18 F-FES SUVmax, a positive trend was noticed (P trend 0.011). Similar results were also showed by Dehdashti et al. [20] They found good overall agreement (88%) between in vitro ER assays and 18 F-FES PET, however was unable to demonstrate any significant relationship between tumor The main limitation of this study is the small number of the patients and the nonavailability of histopathology at most sites. 18 F-FES PET-CT uptake was considered to be reference in controversial position with 18 F-FDG PET-CT. To do biopsy from all metastatic sites is neither possible nor ethically acceptable. 
Conclusion
We are highlighting the role of 18 F-FES PET-CT in comparison to 18 F-FDG PET-CT. 18 F-FDG has overall better sensitivity than 18 F-FES PET-CT; however for nonhepatic metastatic disease sites, no statistically significant difference was found.
18 F-FES PET-CT showed incremental value in characterizing 27.5% of 18 F-FDG-positive lesions and also showed 7.4% exclusive lesions. With this, it has impacted 20% patient's management. We conclude that 18 F-FES PET-CT can be used along with 18 F-FDG PET-CT in strongly ER expressing patients for better specificity, evaluation of disease extent, and impact on treatment.
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